Dreyer Babich Buccola Wood Campora, LLP

Sacramento: 916-379-3500

Auburn: 530-889-1800

San Jose: 408-275-1300

Carmel by the Sea: 831-293-6003

Orange County: 949-517-0425

Se Habla Español | Chúng Tôi Nói Tiếng Việt | Falo Português

We Make A Difference

We provide our clients with the highest quality legal representation
for their injury or loss of a loved one

  1. Home
  2.  » 
  3. Results
  4.  » Armstead v. USC Lawsuit Reaches Resolution

Armstead v. USC Lawsuit Reaches Resolution

Settlement: Confidential | Los Angeles | Armstead v. USC

Due to the level of interest in the matter of Armstead v. USC, University Park Health Center, and James Tibone, Armond Armstead and his counsel, Roger A. Dreyer and Robert B. Bale of the law firm Dreyer Babich Buccola Wood Campora are issuing the following press release:

The parties in this matter have reached a resolution of the case. As a result, the trial scheduled for April 6, 2015, will not proceed. The terms and conditions of the settlement are confidential. As a result, the parties are not at liberty to discuss the litigation or the resolution of the matter. The court file does remain public record.

Mr. Armstead believes that Toradol, a powerful nonsteroidal anti-inflammatory drug (NSAID), and its use as a painkiller in college athletics should be more fully and independently evaluated to protect the health and safety of student athletes, especially those athletes who compete at the intercollegiate level. He believes that these athletes in particular are too often in a vulnerable position, without the resources or information necessary to make informed decisions regarding the use of Toradol, especially in “game day” circumstances where the drug might be used to get a player on the field in spite of an injury, when more conservative medical care might be more appropriate for the long-term health of the student athlete. Mr. Armstead believes that the use of Toradol has not been adequately researched with respect to possible long-term consequences, especially when administered to student athletes by team doctors repeatedly over the course of a season. In Mr. Armstead’s opinion, college teams and team doctors should be required to inform student athletes of the known risks associated with the use of Toradol, including, at a minimum, being provided the warnings and medication guides approved and required for this drug by the Food and Drug Administration. Mr. Armstead believes that the repeated use of Toradol poses certain medical risks to student athletes. Those risks should be scientifically evaluated in a clinical and controlled setting, not in an environment where team doctors are using the drug where the focus may be on the outcome of a single game rather than on protecting the health and safety of individual players. It is his hope that above all, the NCAA and all college football programs will adopt a commitment to always put the individual safety of student athletes ahead of the need to win.

Mr. Armstead extends his deepest appreciation and thanks to his family, friends and fans in Los Angeles, Sacramento, Toronto and Boston and across the country who have supported him over the past four years, and he looks forward to the next chapter of his life.